Remove Biopharmaceuticals Remove Biotechnology Remove Government Remove IT partnerships
article thumbnail

Growth Perspectives: Key Highlights from DCAT 2024

Frost & Sullivan

FUJIFILM Diosynth Biotechnologies invested $1.6 AbbVie introduced a customized risk-based governance model for agile and compliant operations in a highly regulated and risk-sensitive environment. A vital requirement is to successfully scale the formulation from clinical to commercial manufacturing quickly.